Patients Characteristic | PDS (108 patients) | NACT + IDS (49 patients) | |
---|---|---|---|
Age (years) | 59,3 (28 - 85) | 61,2 (34 – 80) | 0,197 |
BMI | 23,8 (18,6 – 34,6) | 23,8 (17 – 42,9) | 0,424 |
Parity (number) | 2 (0 – 8) | 2 (0 – 5) | 0,125 |
Age at last period (years) | 50 (40 – 60) | 50 (42 – 58) | 0,210 |
preop CA125 (units/mL) | 435,0 (14,0 - 21156,0) | 770,0 (68,0 - 36130,0) | 0,059 |
Yes | 74,1 (80) | 89,8 (44) | 0,033 |
No | 25,9 (28) | 10,2 (5) | |
1 | 16,7 (18) | 10,2 (5) | 0,559 |
2 | 53,7 (58) | 61,2 (30) | |
3 | 28,7 (31) | 26,5 (13) | |
4 | 0,9 (1) | 2,0 (1) | |
serous | 66,7 (72) | 85,7 (42) | 0,071 |
endometriod | 25,0 (27) | 12,2 (6) | |
mucinous | 4,6 (5) | 0 (0) | |
clear cells | 3,7 (4) | 2,0 (1) | |
III | 95.4 (103) | 87.7 (43) | 0,08 |
IIa | (8) | (1) | |
IIIb | (25) | (0) | |
IIIc | (70) | (42) | |
IV | 4.6 (5) | 12.3 (6) | |
0 mm (RD = 0) | 53,7 (58) | 77,6 (38) | 0,020 |
1-10 mm (RD = 1) | 17,6 (19) | 8,2 (4) | |
> 10 mm (RD = 2) | 28,7 (31) | 14,3 (7) | |
Yes | 79,6 (86) | 87,8 (43) | 0,265 |
No | 20,4 (22) | 12,2 (6) | |
Alive | 35,2 (38) | 22,4 (11) | |
Death | 64,8 (70) | 77,6 (38) | 0,575 |
Length of follow-up (months) | 41,7 (1,4 - 100,0) | 34,5 (7,6 - 91,0) | 0,21 |
NACT + IDS group | |||
---|---|---|---|
Cycles of NACT | 5 (3 – 6) | ||
Carboplatin | 8,2 (4) | ||
Carboplatin and Paclitaxel | 87,8 (43) | ||
Carboplatin and Doxorubicin | 4,1 (2) | ||
Complete | 20,4 (10) | ||
Partial | 79,6 (39) | ||
Interval LPS to NACT (weeks) | 3 (2 – 5) | ||
Interval NACT to IDS (weeks) | 3 (2 - 8) | ||
Cycles of ACHT | 6 (2 - 9) | 3 (2 – 9) | 0,000 |
Carboplatin | 7,4 (8) | 8,2 (4) | |
Carboplatin and Paclitaxel | 88,0 (95) | 87,8 (43) | 1,000 |
Carboplatin and Doxorubicin | 4,6 (5) | 4,1 (2) | |
Interval PDS to ACTH and IDS to ACTH | 4 (3 - 10) | 4 (2 - 7) | 0,147 |
Yes | 78,9 (56) | 79,1 (34) | 0,588 |
No | 21,1 (15) | 20,9 (9) |
Variables | PDS (108 patients) | NACT + IDS (49 patients) | |
---|---|---|---|
LPS explorative | 47,2 (51) | 100 (49) | |
Blood Loss (ml) | 500,0 (100 - 5000) | 400,0 (50 – 2000) | 0,0001 |
EC units | 2 (1 – 23) 44 patients | 2 (2-3) 12 patients | 0,019 |
Yes | 40,7 (44) | 24,5 (12) | 0,035 |
No | 59,3 (64) | 75,5 (37) | |
Hospitalization Lenght | 15 (7 - 62) | 12 (5 -38) | 0,003 |
No/Grade I-II | 77,8 (84) | 93,9 (46) | 0,009 |
Grade III-IV | 22,2 (24) | 6,1 (3) | |
Yes | 18,6 (16) | 25,6 (11) | 0,174 |
No | 81,4 (70) | 74,4 (32) |
PFS | OS | |||
---|---|---|---|---|
Median (months) | 95% CI (months) | Median (months) | 95% CI (months) | |
PDS | ||||
0 mm (RD = 0) | 20,7 | 13,2 - 28,3 | 54,7 | 40,6 - 68,7 |
1-9 mm (RD = 1) | 11,2 | 10,2 - 12,2 | 34,7 | 0,00 - 71,1 |
> 10 mm (RD = 2) | 13,3 | 10,0 - 16,5 | 31,3 | 15,6 - 47,0 |
General | 17,3 | 15,0- 19,5 | 41,3 | 31,2 - 51,3 |
0 mm (RD = 0) | 19,9 | 16,1 - 23,7 | 36,3 | 27,7 - 44,8 |
1-9 mm (RD = 1) | 14,5 | 2,7 - 26,3 | 25,6 | 3,9 - 47,2 |
> 10 mm (RD = 2) | 8,0 | 6,0 - 9,9 | 16,1 | 8,1 - 24,0 |
General | 18,3 | 14,9 - 21,8 | 34,5 | 26,6 - 42,4 |
Variables | Univariate HR (95% CI) | p | Multivariate HR (95% CI) | p |
---|---|---|---|---|
All sample (157) | ||||
Treatment group | ||||
PDS | 1.00 (reference) | |||
NACT + IDS | 1,34 (0,90 – 1,99) | 0,14 | 1,45 (0,87 – 2,42) | 0,14 |
0 mm (RD = 0) | 1.00 (reference) | |||
1-9 mm (RD = 1) | 1,51 (0,88 - 2,60) | 0,13 | 1,66 (0,96 – 2,82) | 0,06 |
> 10 mm (RD = 2) | 2,29 (1,49- 3,53) | 0,0001 | 2,82 (1,79 – 4,46) | 0,0001 |
< 60 | 1.00 (reference) | |||
≥ 60 | 1,33 (0,91 - 1,95) | 0,13 | 0,91 (0,61 – 1,38) | 0,68 |
I - II | 1.00 (reference) | |||
III - IV | 2,29 (1,53 – 3,41) | 0,0001 | 2,21 (1,44 – 3,40) | 0,0001 |
ACHT cycles | 0,94 (0,82 – 1,08) | 0,42 | 0,99 (0,85 – 1,16) | 0,96 |
Residual Disease | ||||
0 mm (RD = 0) | 1.00 (reference) | |||
1-9 mm (RD = 1) | 1,70 (0,89 – 3,26) | 0,10 | 2,12 (1,08 – 4,15) | 0,028 |
> 10 mm (RD = 2) | 2,37 (1,40 – 4,0) | 0,001 | 3,12 (1,80 – 5,41) | 0,00005 |
< 60 | 1.00 (reference) | |||
≥ 60 | 1,49 (0,93 – 2,39) | 0,09 | 0,81 (0,48 – 1,37) | 0,44 |
I - II | 1.00 (reference) | |||
III - IV | 3,44 (2,08 – 5,68) | 0,001 | 4,40 (2,50 – 7,75) | 0,0001 |
ACHT cycles | 0,77 (0,51 – 1,16) | 0,22 | 0,70 (0,53 – 0,93) | 0,015 |
Residual Disease | ||||
0 mm (RD = 0) | 1.00 (reference) | |||
1-9 mm (RD = 1) | 1,38 (0,47 – 3,98) | 0,55 | 1,53 (0,52 – 4,52) | 0,43 |
> 10 mm (RD = 2) | 4,92 (2,04 – 11, 88) | 0,0001 | 6,67 (2,43 -18,33) | 0,0001 |
< 60 | ||||
≥ 60 | 0,95 (0,50 – 1,81) | 0,88 | 0,71 (0,35 – 1,47) | 0,36 |
I - II | ||||
III - IV | 0,99 (0,48 – 2,01) | 0,97 | 0,77 (0,35 – 1,69) | 0,52 |
ACHT cycles | 1,01 (0,85 – 1,19) | 0,89 | 1,03 (0,86 – 1,23) | 0,70 |